Phase 3
With nipocalimab, Janssen is hoping to take one big swing and knock the power right out of these autoantibodies.
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week’s clinical trial news.
The FDA’s decision to approve Purdue’s drug Nalmefene earned mixed reactions, especially as the company is in the middle of lawsuits. Here’s what you need to know.
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.
Biopharma companies are continuously working to test new treatments to the market. Here are three clinical updates announced this week, spanning three different continents.
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.
Marinus Pharmaceuticals reported that its Phase III RAISE trial of IV ganaxolone for status epilepticus will be delayed, thanks to the pandemic.
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
PRESS RELEASES